Ru(II)-diphosphine/N,S-mercapto complexes and their anti-melanoma properties

Area of Science:

• Coordination Chemistry
• Medicinal Chemistry
• Cancer Biology

Background:

• Melanoma is an aggressive skin cancer with limited treatment options.
• Ruthenium complexes are explored as potential anticancer agents due to their diverse reactivity.
• Developing novel chemotherapeutics with improved efficacy and selectivity is crucial.

Purpose of the Study:

• Synthesize and characterize novel ruthenium complexes.
• Evaluate the cytotoxicity of these complexes against melanoma cell lines.
• Compare their efficacy with cisplatin and investigate their interaction with biomolecules.

Main Methods:

• Synthesis and characterization of five ruthenium complexes: [RuCl(N-S)(dppm)2]PF6 (Ru1), [Ru(N-S)(dppm)2]PF6 (Ru2), [Ru(N-S)(dppe)2]PF6 (Ru3), [Ru(N-S)(dppen)2]PF6 (Ru4), [Ru(N-S)(bpy)2]PF6 (Ru5).
• Cytotoxicity assays using murine melanoma (B16-F10), human melanoma (A-375), and non-tumoral human keratinocyte (HaCat) cell lines.
• In vitro studies including colony formation, cell morphology, cell migration assays, DNA binding, and Human Serum Albumin (HSA) interaction studies.

Main Results:

• All synthesized ruthenium complexes demonstrated dose-dependent inhibition of melanoma cell growth.
• [Ru(2mq)(dppen)2]PF6 exhibited significant cytotoxicity against A-375 cells, showing greater activity than against HaCat cells.
• This complex also inhibited colony formation, altered cell morphology, and reduced cell migration in A-375 cells at low concentrations (0.2-0.4 μM).

Conclusions:

• Ruthenium complexes containing phosphine ligands and 2-mercapto-4(3H)-quinazoline (H2mq) show promising cytotoxic effects against melanoma.
• The complex [Ru(2mq)(dppen)2]PF6 displays selective toxicity towards melanoma cells.
• These findings suggest potential for developing novel ruthenium-based metallodrugs for melanoma treatment.